Phospho-IKBKG (Ser31) Antibody

What is the biological significance of IKBKG phosphorylation at Serine 31?

IKBKG (also known as NEMO or NF-kappa-B essential modulator) phosphorylation at Serine 31 represents a critical regulatory event in the NF-κB signaling pathway. This specific phosphorylation occurs within the amino acid region 16-65 and modulates IKBKG activity, serving as a vital marker for investigating signaling pathways involved in inflammation, immunity, and cell survival . The phosphorylation of IKBKG at Ser31 occurs downstream of various stimuli, including TNF-α stimulation, as demonstrated in Western blot analysis of lysates from 293 cells treated with TNF-α (20ng/ml for 5 minutes) . This post-translational modification affects the protein's function as a regulatory subunit of the IκB kinase (IKK) complex, which is required for the activation of the NF-κB pathway in response to multiple cellular stimuli.

How do researchers distinguish between phosphorylated and non-phosphorylated forms of IKBKG?

Distinguishing between phosphorylated and non-phosphorylated forms of IKBKG requires specialized antibodies that recognize specific phosphorylation states. Phospho-IKBKG (Ser31) antibodies are designed to detect endogenous levels of IKK-gamma protein only when phosphorylated at Ser31 . These antibodies are typically produced by immunizing rabbits with synthetic phosphopeptides derived from the human IKK-gamma around the phosphorylation site .

The specificity is ensured through a two-step purification process:

• Affinity-purification from rabbit antiserum using epitope-specific immunogen

• Removal of non-phospho specific antibodies by chromatography using non-phosphopeptide

Validation experiments typically include blocking with the phospho-peptide during Western blot or immunohistochemistry analysis, which should eliminate the signal if the antibody is truly phospho-specific .

What is the relationship between IKBKG and the broader NF-κB signaling pathway?

IKBKG functions as the regulatory subunit of the IKK complex, which is essential for activating the NF-κB pathway. The canonical NF-κB signaling pathway is initiated in response to numerous stimuli including T cell and B cell receptor engagement, growth factors, and inflammatory stimuli such as reactive oxygen species, TNF-α, and IL-1 .

The activation sequence involves:

• Stimulation of receptors leads to activation of the IKK complex (containing IKKα, IKKβ, and IKBKG/NEMO)

• IKK phosphorylates IκBα, resulting in its ubiquitination and degradation

• This releases NF-κB transcription factor proteins, allowing their translocation into the nucleus

• Nuclear NF-κB regulates genes involved in inflammation, immunity, and cell survival

IKBKG is essential in this process as it coordinates the assembly and activation of the IKK complex. Mutations in IKBKG can lead to severe immune deficiencies and other disorders, highlighting its critical role in immune function .

What are the recommended applications and dilutions for Phospho-IKBKG (Ser31) antibodies?

Based on manufacturer specifications, Phospho-IKBKG (Ser31) antibodies can be used in multiple research applications with the following recommended dilutions:

These dilutions should be optimized based on the specific research application and sample type . For Cell-Based ELISA applications, specialized kits are available that can detect both phosphorylated and total IKBKG to normalize results .

How should researchers design experiments to study IKBKG phosphorylation dynamics?

When designing experiments to study IKBKG phosphorylation dynamics, researchers should consider the following methodological approach:

• Selection of appropriate stimuli: TNF-α (20ng/ml) treatment for 5-30 minutes has been demonstrated to effectively induce IKBKG phosphorylation at Ser31 .

• Time-course experiments: Include multiple time points (0, 5, 15, 30 minutes) to capture the transient nature of phosphorylation events .

• Appropriate controls:

  • Unstimulated cells as negative controls

  • Phosphatase inhibitors in lysis buffers to preserve phosphorylation status

  • Blocking with the phospho-peptide as specificity control

  • Parallel detection of total IKBKG for normalization

• Multiple detection methods: Combine Western blot with other techniques like cell-based ELISA or proximity ligation assay for comprehensive analysis .

• Genetic approaches: Consider using IKBKG-deficient cell lines (like IKBKG-deficient HEK293T cells) transfected with wild-type or mutant IKBKG to study functional consequences of phosphorylation .

For cell-based detection systems, ensure cells are properly fixed to preserve phosphorylation status before antibody incubation.

What are the optimal storage conditions for maintaining Phospho-IKBKG (Ser31) antibody activity?

To maintain optimal activity of Phospho-IKBKG (Ser31) antibodies, researchers should adhere to the following storage recommendations:

• Store antibodies at -20°C or -80°C for long-term storage .

• Avoid repeated freeze-thaw cycles by preparing small aliquots upon receipt .

• For working stocks, antibodies are typically formulated in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide to maintain stability .

• Return antibodies to appropriate storage temperatures immediately after use .

• Most manufacturers guarantee stability for up to 1 year from the date of receipt when stored properly .

Improper storage can lead to antibody degradation, resulting in reduced specificity and sensitivity in experimental applications.

How do different phosphorylation sites on IKBKG influence its function in the NF-κB pathway?

IKBKG undergoes phosphorylation at multiple sites, each with distinct functional implications for NF-κB signaling:

• Ser31 phosphorylation: Located in the amino acid region 16-65, this modification occurs in response to TNF-α stimulation and plays a role in modulating IKBKG activity in the canonical NF-κB pathway .

• Ser85 phosphorylation: Targeted by cell-based ELISA kits, this site has distinct regulatory functions compared to Ser31 .

• Ser376 phosphorylation: IKKβ has been shown to phosphorylate IKBKG at serine 376 in response to signaling through the TNF receptor or the Tax oncoprotein of human T-cell leukemia virus type 1 .

• Ser68 phosphorylation: Attenuates aminoterminal homodimerization, affecting IKBKG's ability to form functional complexes .

These different phosphorylation events work in concert with other post-translational modifications, including polyubiquitination on Lys-285 via 'Lys-63'-linked ubiquitin mediated downstream of NOD2 and RIPK2, as well as polyubiquitination on Lys-285 and Lys-399 through 'Lys-63'-linked ubiquitin mediated by BCL10, MALT1, and TRAF6 . The complex interplay between these modifications creates a sophisticated regulatory network that fine-tunes NF-κB pathway activation in response to various stimuli.

What experimental approaches can differentiate between IKBKG phosphorylation at Ser31 versus other phosphorylation sites?

Differentiating between phosphorylation at Ser31 and other sites requires a strategic experimental approach:

• Site-specific phospho-antibodies: Use antibodies that specifically recognize IKBKG phosphorylated at Ser31, Ser85, or Ser376 . Validation should include peptide competition assays with phospho and non-phospho peptides.

• Proximity Ligation Assay (PLA): This technique can visualize specific phosphorylation events at the single-molecule level. An antibody pair set consisting of a phospho-site-specific antibody and a total IKBKG antibody can be used to detect specific phosphorylation events in situ .

• Mass spectrometry analysis: For unbiased identification and quantification of all phosphorylation sites on IKBKG.

• Phospho-site mutants: Generate IKBKG constructs with serine-to-alanine mutations at specific sites (S31A, S85A, S376A) and analyze their functional impact when expressed in IKBKG-deficient cells.

• Phosphatase treatments: Compare the effects of broad-spectrum versus site-specific phosphatases on antibody recognition.

An experimental workflow might involve parallel Western blots probed with different phospho-site-specific antibodies, followed by validation using mutant constructs and functional assays to determine the biological significance of each phosphorylation event.

How do IKBKG mutations affect its phosphorylation status and subsequent NF-κB activation?

IKBKG mutations have profound effects on phosphorylation status and NF-κB activation, as revealed by multiple studies:

• A nonsense mutation (c.924 C > G, p.Tyr308*) identified in a Chinese patient with incontinentia pigmenti (IP) resulted in a truncated NEMO protein that completely inhibited NF-κB activity when stimulated by lipopolysaccharide. This mutant exhibited severely impaired phosphorylation of p65 and degradation of IκBα .

• The panr2 mutation in mice impaired MAPK and p105 phosphorylation, p65 translocation, and TNF production, despite normal IκBα degradation. This selective loss of function highlights the importance of NEMO-regulated pathways beyond IκBα degradation and offers biochemical explanations for rare immune deficiencies .

• A germline missense mutation in human IKBKB (encoding IKK2) conferred gain of function, resulting in increased phosphorylation of p65, particularly in the T cell compartment, with enhanced response to activation stimuli persisting up to 60 minutes .

These findings demonstrate that mutations in IKBKG or its associated proteins can selectively impact specific branches of NF-κB signaling, resulting in distinct immune phenotypes. The study of phosphorylation status in these mutant contexts provides valuable insights into the mechanisms of pathway regulation and disease pathogenesis.

What are common challenges in detecting phosphorylated IKBKG and how can researchers overcome them?

Researchers frequently encounter several challenges when detecting phosphorylated IKBKG:

• Low signal intensity:

  • Solution: Optimize antibody concentration and incubation conditions

  • Enhance signal using more sensitive detection systems (e.g., chemiluminescent substrates with longer exposure times)

  • Enrich for phosphorylated proteins using phospho-protein enrichment kits before Western blotting

• High background:

  • Solution: Increase blocking stringency (5% BSA is often preferred over milk for phospho-epitopes)

  • Extend washing steps and use detergents like Tween-20 at appropriate concentrations

  • Optimize primary antibody dilution based on the recommended range (1:500-1:2000 for WB)

• Rapid dephosphorylation during sample preparation:

  • Solution: Use phosphatase inhibitor cocktails in lysis buffers

  • Maintain samples at 4°C during processing

  • Use rapid protein extraction methods

• Cross-reactivity with other phosphorylated epitopes:

  • Solution: Include peptide competition controls with phospho and non-phospho peptides

  • Use IKBKG-deficient cells as negative controls

  • Verify results with multiple antibodies targeting the same phospho-site

• Variable phosphorylation levels due to cell culture conditions:

  • Solution: Standardize cell culture conditions

  • Include positive controls (e.g., TNF-α stimulated cells for 5 minutes)

  • Use time-course experiments to capture optimal phosphorylation windows

For cell-based detection methods, proper fixation is crucial to preserve phosphorylation status, and antibody dilutions may need to be adjusted compared to Western blot applications.

How should researchers interpret conflicting data between different detection methods for phosphorylated IKBKG?

When faced with conflicting data between different detection methods for phosphorylated IKBKG, researchers should:

• Consider methodological differences:

  • Western blot detects denatured proteins, potentially exposing epitopes that might be masked in native conformations

  • Immunohistochemistry and immunofluorescence detect proteins in their cellular context, allowing for localization studies

  • ELISA provides quantitative data but may be affected by epitope accessibility

• Evaluate antibody performance across methods:

  • Some antibodies perform better in certain applications

  • Validate antibody specificity in each method using appropriate controls

  • Consider using multiple antibodies targeting the same phospho-site

• Implement orthogonal approaches:

  • Combine antibody-based methods with genetic approaches (phospho-mimetic mutations)

  • Use mass spectrometry for unbiased verification

  • Apply proximity ligation assay (PLA) to detect specific phosphorylation events at the single-molecule level

• Biological context matters:

  • Phosphorylation is dynamic and transient

  • Different cell types may exhibit different phosphorylation patterns

  • Stimulation conditions critically affect phosphorylation status

• Integrate data hierarchically:

  • Prioritize results from multiple converging methods

  • Consider quantitative methods (ELISA) for measuring differences in phosphorylation levels

  • Use qualitative methods (IF) for information about subcellular localization

A comprehensive approach might involve validating Western blot findings with cell-based ELISA, confirming localization with immunofluorescence, and supporting functional relevance through mutagenesis studies.

What controls are essential for validating the specificity of Phospho-IKBKG (Ser31) antibody detection?

Rigorous validation of Phospho-IKBKG (Ser31) antibody specificity requires several essential controls:

• Peptide competition assays:

  • Incubate antibody with the phosphorylated peptide used as immunogen

  • Incubate antibody with the corresponding non-phosphorylated peptide

  • A specific phospho-antibody signal should be blocked by the phospho-peptide but not by the non-phospho-peptide

• Phosphatase treatment:

  • Treat one sample set with lambda phosphatase before antibody incubation

  • Signal should be eliminated or significantly reduced compared to untreated samples

• Stimulation/inhibition controls:

  • Use known activators like TNF-α (20ng/ml for 5 minutes) as positive controls

  • Include samples treated with specific IKK inhibitors as negative controls

• Genetic controls:

  • Use IKBKG-deficient cells (e.g., IKBKG-deficient HEK293T cells)

  • Compare cells expressing wild-type IKBKG versus phospho-site mutants (S31A)

• Antibody validation across applications:

  • For Western blot: Confirm band at expected molecular weight (~50-55 kDa)

  • For IHC/IF: Include appropriate tissue/cell type negative controls

  • For ELISA: Include standard curves with recombinant proteins

• Cross-comparison with other phospho-site antibodies:

  • Run parallel detection with antibodies targeting other IKBKG phosphorylation sites

  • Monitor total IKBKG levels alongside phosphorylated forms

These controls should be systematically incorporated into experimental designs to ensure confident interpretation of results involving phosphorylation-specific antibodies.

How might emerging technologies enhance our ability to study IKBKG phosphorylation dynamics in living cells?

Emerging technologies offer promising approaches to study IKBKG phosphorylation with unprecedented temporal and spatial resolution:

• Genetically encoded phosphorylation sensors:

  • Development of FRET-based sensors specifically designed to detect IKBKG phosphorylation at Ser31

  • These would allow real-time monitoring of phosphorylation events in living cells

  • Could reveal the spatiotemporal dynamics of IKBKG activation in response to various stimuli

• Super-resolution microscopy:

  • Techniques like STORM, PALM, or STED combined with phospho-specific antibodies

  • Would enable visualization of phosphorylated IKBKG at nanometer resolution

  • Could reveal previously unknown subcellular compartmentalization of phospho-IKBKG

• Mass spectrometry innovations:

  • Novel techniques for single-cell phosphoproteomics

  • Would allow analysis of IKBKG phosphorylation heterogeneity within cell populations

  • Could identify cell-specific phosphorylation patterns in complex tissues

• CRISPR-based approaches:

  • Development of CRISPR activation/inhibition systems targeting kinases responsible for IKBKG phosphorylation

  • Creation of phospho-site-specific knock-in mutations for precise functional studies

  • Generation of cellular reporters with endogenously tagged IKBKG

• Antibody engineering:

  • Development of intrabodies or nanobodies specifically recognizing phosphorylated IKBKG

  • These could be expressed in cells to track phosphorylation in real-time

  • May offer improved specificity and reduced interference with normal cellular functions

These technological advances would significantly enhance our understanding of the dynamic regulation of IKBKG phosphorylation and its role in NF-κB signaling pathways in physiological and pathological conditions.

What are the implications of IKBKG phosphorylation status for potential therapeutic interventions targeting the NF-κB pathway?

Understanding IKBKG phosphorylation status has significant implications for developing targeted therapeutics:

• Phosphorylation-specific inhibitors:

  • Development of small molecules specifically blocking IKBKG phosphorylation at Ser31

  • These could offer more selective modulation of NF-κB activity compared to broad IKK inhibitors

  • Could potentially reduce side effects associated with complete NF-κB inhibition

• Disease-specific targeting:

  • Mutations in IKBKG cause diverse conditions including immune deficiencies and incontinentia pigmenti

  • Phosphorylation patterns may differ between disease states

  • Therapeutics could be designed to normalize specific phosphorylation abnormalities

• Precision medicine applications:

  • Phosphorylation status could serve as a biomarker for disease activity

  • Patient stratification based on IKBKG phosphorylation profiles

  • Monitoring phosphorylation as a measure of treatment efficacy

• Combination therapy strategies:

  • Targeting phosphorylation in combination with other post-translational modifications

  • Synergistic approaches targeting both phosphorylation and ubiquitination pathways

  • Integration with existing immunomodulatory approaches

• Phosphorylation-guided gene therapy:

  • For genetic disorders caused by IKBKG mutations

  • Design of gene therapy constructs with modified phosphorylation sites

  • Could restore normal signaling without complete protein replacement

Progress in this area would benefit from further research into the specific functional outcomes of different IKBKG phosphorylation events and their relative contributions to pathological NF-κB signaling in various disease contexts.

How do genetic variants in IKBKG affect phosphorylation-dependent signaling networks across different cell types and disease states?

Genetic variants in IKBKG create complex effects on phosphorylation-dependent signaling across cellular and disease contexts:

• Cell type-specific effects:

  • The panr2 mutation in mice showed that degradation of IκBα occurred normally in response to TLR stimulation, yet ERK phosphorylation and NF-κB p65 nuclear translocation were severely impaired

  • This selective loss of function highlights cell type-specific dependencies on NEMO-regulated pathways

  • Studies in T cells, B cells, and macrophages reveal different phosphorylation requirements for functional NF-κB activation

• Pathway crosstalk modulation:

  • IKBKG variants affect interactions between NF-κB and other signaling networks:

    • A nonsense mutation (p.Tyr308*) completely inhibited both p65 phosphorylation and IκBα degradation

    • The panr2 mutation impaired MAPK phosphorylation despite normal IκBα degradation

  • These findings suggest that IKBKG phosphorylation coordinates multiple signaling cascades beyond canonical NF-κB activation

• Disease-specific phosphorylation patterns:

  • Germline missense mutations in IKBKB result in gain of function with increased p65 phosphorylation in immune cells

  • IKBKG polymorphisms may influence susceptibility to complex diseases, as investigated for age-related macular degeneration

  • The functional impact of these variants on phosphorylation-dependent signaling remains to be fully elucidated

• Developmental context:

  • IKBKG is required for complete lymph node development and for proper development of regulatory T cells and NKT cells

  • Phosphorylation requirements may differ during development versus adult immune responses

  • Temporal regulation of phosphorylation could explain why some IKBKG mutations affect specific developmental processes